Mannitol

Q: What side effects can mannitol cause?

Mannitol (Mannitolum) can cause certain adverse effects across various body systems. Common adverse reactions include: General symptoms — weakness, dry mouth;Cardiovascular system — tachycardia;Central nervous system — risk of seizures.

Q: What are the contraindications for mannitol use?

Contraindications for mannitol (Mannitolum) depend on the clinical scenario and formulation. They include: Hypernatremia — serum sodium levels at or above the upper limit of normal due to the risk of exacerbating cellular swelling;Anuria due to severe renal disease — limits its use when treating cerebral edema;Pediatric age — specific contraindications depend on the formulation (e.g., inhalation powder is restricted in young children).

Q: How does mannitol affect electrolyte excretion (sodium, potassium, chloride)?

Mannitol (Mannitolum) causes a secondary and negligible decrease in sodium ion ($Na^+$) reabsorption. This occurs because water is retained in the tubular lumen due to the drug's high osmotic activity, significantly increasing tubular urine volume. Direct effects of mannitol on potassium and chloride excretion are not primary mechanisms of action.

Mannitum

For medical students2 min readUpdated 2026-10-10

Mannitol (Mannitum) is a potent osmotic diuretic whose action relies on physicochemical laws rather than receptor blockade. The drug creates a high osmotic pressure in the renal tubules and plasma, effectively "pulling" excess fluid out of tissues and increasing diuresis.

Pharmacological classOsmotic diuretics

Mechanism of actionIncreasing osmotic pressure within the tubular lumen

ExcretionRapid (30–60 min) via glomerular filtration

Key featureDoes not cross the blood-brain barrier (BBB); dehydrates brain tissue

Mechanism of Action

Mannitol (Mannitum / Mannitolum) differs fundamentally from other diuretics (such as furosemide, acetazolamide, or spironolactone). Its action is based exclusively on physicochemical properties—it does not interact with epithelial enzymes or cellular receptors.

Following intravenous administration, the drug is filtered through the capillaries of the renal glomeruli and enters the lumen of the nephron tubules. Mannitol undergoes virtually no tubular reabsorption and acts throughout the entire tubular system. The key sites of its action are areas of free water reabsorption via aquaporins:

Proximal tubules;
Descending limb of the loop of Henle;
Collecting ducts.

Present within the lumen, the drug creates and maintains high osmotic pressure, preventing the passive reabsorption of water.

Pharmacological Effects

There are two main directions of the drug's action:

Diuretic effect. Due to its high osmotic activity, mannitol retains water in the tubular lumen. This leads to a significant increase in urine volume. Sodium ion reabsorption is secondarily (and very negligibly) reduced.
Dehydrating effect. While in the bloodstream, the drug increases plasma osmotic pressure. Because mannitol poorly penetrates biological membranes (tissue barriers), it establishes a pressure gradient that drives fluid shift from tissues into the vascular bed. This is especially effective for tissues protected by blood-tissue barriers (brain tissue, eyeball).

Clinical pearl: The osmotic action of mannitol is sometimes used to artificially disrupt the blood-brain barrier (BBB). Elevating osmotic pressure disrupts the structure of capillary endothelial tight junctions, increasing paracellular transport. This allows for better delivery of chemotherapy drugs in malignant brain tumors.

Pharmacokinetics

The drug does not undergo hepatic biotransformation (metabolism) in the body. It is excreted unchanged via glomerular filtration. Elimination is very rapid, with the majority excreted within 30 to 60 minutes after intravenous administration.

Indications

Due to its unique properties, mannitol is widely used in emergency medicine and critical care:

Cerebral edema: Utilizing the drug's potent dehydrating capability.
Acute angle-closure glaucoma: For rapid reduction of intraocular pressure.
Chemical poisonings: As part of forced diuresis protocols to accelerate toxin elimination (often combined with 1–2 L of 0.9% NaCl solution or loop diuretics).
Oliguria: In conditions associated with impaired hemodynamics (trauma, burns, blood loss) to maintain glomerular filtration.

Side Effects

Administration of mannitol may be accompanied by the following adverse reactions:

General symptoms: Weakness, dry mouth.
Cardiovascular system: Tachycardia.
Central nervous system: Risk of seizure activity.

Administration and Dosage

The drug is administered exclusively intravenously (as an IV push or infusion).

Dosage: Calculated as 0.5–1.5 g/kg of body weight. The maximum daily dose is 140–180 g.
Formulations:
15% solution in 200, 400, and 500 mL vials/bottles.
Powder in 30 g vials. Solutions from powder are prepared ex tempore (immediately before use) by dissolving in 200 mL of sterile water for injection or a 5% glucose solution.

Mnemonic

Mannitol works like an OSMOTIC SPONGE: it doesn't cross barriers or get reabsorbed, but pulls water out of tissues (brain, eye) and holds it tightly within the renal tubules.

Frequently asked questions

What side effects can mannitol cause?

Mannitol (Mannitolum) can cause certain adverse effects across various body systems. Common adverse reactions include:

General symptoms — weakness, dry mouth;
Cardiovascular system — tachycardia;
Central nervous system — risk of seizures.

What are the contraindications for mannitol use?

Contraindications for mannitol (Mannitolum) depend on the clinical scenario and formulation. They include:

Hypernatremia — serum sodium levels at or above the upper limit of normal due to the risk of exacerbating cellular swelling;
Anuria due to severe renal disease — limits its use when treating cerebral edema;
Pediatric age — specific contraindications depend on the formulation (e.g., inhalation powder is restricted in young children).

How does mannitol affect electrolyte excretion (sodium, potassium, chloride)?

Mannitol (Mannitolum) causes a secondary and negligible decrease in sodium ion ($Na^+$) reabsorption. This occurs because water is retained in the tubular lumen due to the drug's high osmotic activity, significantly increasing tubular urine volume. Direct effects of mannitol on potassium and chloride excretion are not primary mechanisms of action.

Why is mannitol effective in cerebral edema?

It does not cross an intact blood-brain barrier (BBB). By increasing plasma osmolarity, the drug creates a pressure gradient that draws excess fluid from the brain tissue into the vascular compartment.

In which parts of the nephron does mannitol act?

Along the entire length of the tubules, with key sites being the zones of free water reabsorption via aquaporins: the proximal tubules, the descending limb of the loop of Henle, and the collecting ducts.

Does mannitol bind to renal receptors?

No. It is the only diuretic whose mechanism relies solely on physicochemical properties (increasing osmotic pressure) rather than interacting with enzymes or receptors.

Does mannitol undergo metabolism?

No, it is not metabolized in the body and is rapidly excreted unchanged via glomerular filtration within 30 to 60 minutes.

Go deeper

Comparative pharmacology of osmotic and loop diuretics
Protocols for forced diuresis in acute poisonings
Blood-tissue barriers: BBB and blood-aqueous barrier
Paracellular transport and the structure of tight junctions
Oliguria in shock states: pathophysiology and the role of diuretics